205037-66-7

Basic information

• Product Name: N-(4-chlorophenyl)-8-hydroxyquinoline-7-carboxamide
• Synonyms: N-(4-chlorophenyl)-8-hydroxyquinoline-7-carboxamide
• CAS NO: 205037-66-7
• Molecular Weight: 298.729
• Mol File: 205037-66-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(4-chlorophenyl)-8-hydroxyquinoline-7-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-chlorophenyl)-8-hydroxyquinoline-7-carboxamide(205037-66-7)
• EPA Substance Registry System: N-(4-chlorophenyl)-8-hydroxyquinoline-7-carboxamide(205037-66-7)

Safety Data

• Hazardous Substances Data: 205037-66-7(Hazardous Substances Data)

Upstream product

• 106-47-8 4-chloro-aniline 
• 19829-79-9 8-hydroxy-7-quinolinecarboxylic acid 
• 205040-62-6 5-chloro-8-hydroxyquinoline-7-carboxylic acid 

Relevant articles and documents

SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway

Disruption of cyclic adenosine monophosphate response element binding protein (CREB) provides a potential new strategy to address acute leukemia, a disease associated with poor prognosis, and for which conventional treatment options often carry a significant risk of morbidity and mortality. We describe the structure-activity relationships (SAR) for a series of XX-650-23 derived from naphthol AS-E phosphate that disrupts binding and activation of CREB by the CREB-binding protein (CBP). Through the development of this series, we identified several salicylamides that are potent inhibitors of acute leukemia cell viability through inhibition of CREB-CBP interaction. Among them, a biphenyl salicylamide, compound 71, was identified as a potent inhibitor of CREB-CBP interaction with improved physicochemical properties relative to previously described derivatives of naphthol AS-E phosphate.

INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA

Compounds and methods are provided for inhibiting a CREB-CBP protein-protein interaction in a sample. In some cases, the method includes modulating transcription of CREB in a cell that overexpresses CREB. Also provided are methods of inhibiting the proliferation of a cancer cell. The subject CREB transcription inhibitor compounds include a substituted salicylamide or a prodrug thereof. Methods of alleviating symptoms associated with cancer (e.g., Acute Myeloid Leukemia (AML) or Acute Lymphomblastic Leukemia (ALL)) in a subject in need thereof are also provided. Pharmaceutical compositions including the subject compounds find use in treating cancer. The subject compounds may be formulated or provided to a subject in combination with a second agent, e.g. an anticancer agent.